Document:

EX-10.9

 Exhibit 10.9 

NEITHER THE WARRANTS NOR THE SHARES DELIVERABLE UPON EXERCISE OF THE WARRANTS (THE “WARRANT SHARES”) HAVE BEEN OR WILL BE REGISTERED WITH THE
U.S. SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE
OFFERED OR SOLD EXCEPT IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN
ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO CELLECTIS. 

CELLECTIS 
 WARRANT
AGREEMENT 
 Trout Capital LLC 
 740 Broadway, 9th Floor

 New York, NY 10003 
 United States 

hereinafter referred to as the “Beneficiary” 

On March 24, 2014, the board of directors, using the delegation of competence granted to it by the extraordinary shareholders meeting of CELLECTIS (the
“Company”) held on June 14, 2013, issued and granted to the Beneficiary 50,000 warrants (the “Warrants”) under the terms and conditions set forth in this agreement. 

For the avoidance of doubt, the present document shall in no event be deemed as the certificate referred to in article R. 211-7 of the French Code
monétaire et financier and shall only be deemed, for purposes of French law, to set forth the terms and conditions of the Warrants. 
  

			
	Date of Grant:		March 24, 2014
		
	Subscription Price of the Warrants:		 EUR. 30,000.00
 (i.e., EUR. 0.60 per
Warrant)

		
	 Maximum number of ordinary shares
 (the
“Warrant Shares”) to be subscribed upon exercise of the Warrants:
		50,000 (i.e., 1 Warrant Share per Warrant)
		
	Exercise price per Warrant Share:		EUR 6.00
		
	Term/Expiration date of the Warrants:		2 years from date of grant, i.e. March 24, 2016

 Article 1 - Validity of the Warrants 

The Warrants will be validly issued as from the date of their subscription by the Beneficiary subject to the conditions precedent that the Beneficiary: 

 

	 	(i)	executes and returns to the Company the subscription form of the Warrants in the form attached as exhibit 1 hereto; and 

  

	 	(ii)	pays the Subscription Price in full, in cash or by way of set off against receivables in accordance with applicable French law, on or before March 31, 2014. 

Article 2 - Exercise of the Warrants 
  

	2.1	Vesting period 

 The Warrants may be exercised at any time from their issue date until March 24,
2016. 
 Any Warrant not exercised on or before March 24, 2016 shall be automatically void. 

 

	2.2	Method of Exercise 

 The Warrants are exercisable by delivery of an exercise notice, in the form attached
hereto under exhibit 2 (the “Exercise Notice”), comprising a Warrant Share subscription form (bulletin de souscription) which shall state the Beneficiary’s election to exercise all or parts of the Warrants and the number
of Warrant Shares in respect of which the Warrants are being exercised. The Exercise Notice shall be signed by the Beneficiary and shall be delivered in person or by certified mail to the Company or its designated representative or by facsimile
message to be immediately confirmed by certified mail to the Company. The Exercise Notice shall be accompanied by the payment of the aggregate exercise price (the “Exercise Price”) of all Warrant Shares. If the Exercise Price is
paid by wire transfer, the Exercise Price will have to be paid on the Company’s bank account at the latest within 10 calendar days following the receipt by the Company of the Exercise Notice. The Warrants shall be deemed to be exercised upon
receipt by the Company of such fully executed Exercise Notice accompanied by the proof of payment of such Exercise Price. 
 Warrant Shares shall be issued
and held in registered form in the Beneficiary’s name in a Company shareholders’ account held by the Company or its registrar (currently Société Générale Securities Services) (the “Registrar”),
with an indication of the applicable transfer restrictions set forth herein. The Registrar will arrange for the Warrant Shares to be admitted to Euroclear as soon as possible (consistent with standard practice at the time of exercise) after the
creation of the Warrant Shares. 
 Upon exercise of the Warrants, the Warrant Shares issued to the Beneficiary shall be assimilated with all other ordinary
shares of the Company (other than with respect to the obligation to transfer the Warrants Shares only in an “offshore transaction” as that term is defined in Regulation S under the Securities Act or otherwise in a transaction not requiring
registration under the Securities Act) and shall be entitled to dividend for the fiscal year during which the Warrant Shares are subscribed and issued. 

  
 - 2 - 

	2.3	Payment of the Warrant Shares 

 Payment of the aggregate Exercise Price of the Warrant Shares shall be
made, at the election of the Beneficiary, by: 
  

	 	(1)	bank wire transfer; or 

  

	 	(2)	check; or 

  

	 	(3)	set off against receivables in accordance with applicable French law; or 

  

	 	(4)	any combination of the foregoing methods of payment. 

 Article 3 - Transfer of the warrants 

 

	3.1	Transferability 

 Neither the Warrants nor any Warrant Shares issued upon exercise of the Warrants shall
be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180
days immediately following the date of this agreement, except the transfer of any security: 
  

	i.	by operation of law or by reason of reorganization of the Company; or 

  

	ii.	the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section 3.1 for the remainder of the time period. 

Subject to the foregoing restrictions and compliance with any applicable securities laws, the Warrants and all rights hereunder are transferable, in whole or
in part, upon written notice substantially in the form attached hereto in exhibit 3 (the “Transfer Notice”) duly executed by the Beneficiary or its agent or attorney and sent to the principal office of the Company, together with
wire of funds sufficient to pay any transfer taxes payable upon the making of such transfer on the Company’s bank account following due notification to the Beneficiary. Upon such notice and surrender and, if required, such payment, the Company
shall transcribe the transfer and inscribe the assignee or assignees as Warrantholder(s) in its register and execute and deliver a new Warrant Agreement or Agreements in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant Agreement evidencing that number of Warrants not so assigned, and this Warrant Agreement shall promptly be cancelled. The Warrants, if
properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having new Warrant Agreement(s) executed. Notwithstanding the foregoing, the Company shall have the right to decline to make a
transfer of the Warrant or Warrants if such transfer is in violation of the applicable transfer restrictions described herein. 
  

	3.2	Transfer Restrictions. 

 The Warrants may only be disposed of in compliance with French, U.S., state and
Federal securities laws and in an “offshore transaction” in accordance with Regulation S under the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the
Securities Act. If, at the time of receipt of the Transfer Notice in 

  
 - 3 - 

 
connection with any transfer of the Warrants, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of the Warrants, as the case may be, provide to the
Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require
registration of such transferred Warrant or the Warrant Shares under the Securities Act. 
 Article 4 - Other terms of the Warrants 

In the event of a reduction in the Company’s share capital resulting from losses and implemented through share cancellation, the Beneficiary’s rights
regarding the number of shares to be issued upon exercise of its Warrants shall be reduced accordingly, as if the Beneficiary were a shareholder at the time of such reduction in share capital. 

In the event of a reduction in the Company’s share capital resulting from losses and implemented through reduction of the Company’s shares par
value, the subscription price for the shares issued upon exercise of the Warrants shall not change, and the issuance premium shall be increased in an amount corresponding to the aggregate amount of the reduction of the Company’s shares par
value. 
 In the event of a reduction in the Company’s share capital not resulting from losses and implemented through reduction of the Company’s
shares par value, the subscription price of the shares issued upon exercise of the Warrants shall be reduced accordingly. 
 In the event of a reduction in
the Company’s share capital not resulting from losses and implemented through share cancellation, should the Beneficiary choose to exercise its Warrants, it shall be entitled to request the purchase by the Company of a quantum of shares
(granted upon exercise of the Warrants) under the same conditions as those set in favor of then existing shareholders when such reduction in the Company’s share capital occurred. 

In case of a rights issue (in which all shareholders are offered to participate prorata their respective equity stake), the Company will take one or several
of the following decisions to preserve the rights of Warrants holders, in accordance with the provisions of article L. 228-99 of the French commercial code and applicable French and U.S. securities laws: 

 

	1.	permit any Warrant holder to exercise his Warrants immediately so that such holder may participate in the rights issue, which will not alter or limit the rights of the Beneficiary to exercise the Warrants under
Section 2.1 of this Warrant Agreement; or 

  

	2.	take any measures which would allow the Beneficiary, should he decide to exercise the Warrants, to eventually be in the same position as other shareholders as if the Beneficiary were a shareholder at the time of such
operations. Should the Beneficiary exercise its Warrants, the Company could thus allow the Beneficiary to subscribe a pro rata share of a new rights’ issue or be the beneficiary of free allocation of shares, or receive cash or goods
under the same form, proportion, terms and conditions (except for use) as those set in favor of then existing shareholders when such operations occurred; or 

  
 - 4 - 

	3.	adjust the Warrants’ exercise price, conversion-into-shares ratio or other terms relating to subscription of the Company’s shares in order to take into account the new rights issue. In such case, any such
adjustment shall be carried out in accordance with the method set forth in article R. 228-91 of French Commercial Code (Code de commerce), it being specified that the value of an existing shareholder’s right to participate, as well as
the value of the share itself (including the right to participate in the rights issue), shall be determined by the board of directors of the Company. The board shall determine such value while taking into account, as the case may be, the
subscription, exchange or sale price per share used during the last operation relating to the Company’s share capital (such as any share capital increase, contribution in kind, sale of shares,...) which occurred during a six (6)-month period
immediately preceding such board of directors’ meeting. In the event no such operation occurred over such period, the board shall take into account any other financial parameter which it finds relevant (and which relevancy shall then be
confirmed by the Company’s statutory auditor). 

  The Company is authorized, without requesting the specific consent of the holder
of the Warrants, to modify its corporate form and its corporate purpose. 
 If at any time the Warrants should be held by more than one holder and in
accordance with Article L.228-103 of the French Commercial Code, holders of the Warrants would then be aggregated together in an independent legal entity (the “Masse”) for the defense of their collective rights. 

A general meeting of the holders of the Warrants shall be called to authorize all modifications of the terms and conditions of the Warrants, and to vote on
all decisions and actions that, by law, must be submitted for its approval. 
 The Company may amend the rules regarding profit allocation, amortize the
share capital and create and issue preferred shares entailing any such modification or amortization without requesting the specific consent of the holder of the Warrants subject to complying with the provisions of Article L. 228-98 of the French
Commercial Code. 
 Article 5 - Governing Law 

This agreement is governed by the laws of the Republic of France. 

Any claim or dispute arising under this agreement shall be subject to the exclusive jurisdiction of the court competent for the place of the registered office
of the Company. 
  

									
	 /s/ Jonathan Fassberg
				 /s/ André Choulika

	For TROUT CAPITAL LLC				For CELLECTIS
	By:		Jonathan Fassberg				By:		André Choulika
	Title:		CCO				Title:		Président directeur général (CEO)

  
 - 5 - 

 EXHIBIT 1 

SUBSCRIPTION FORM OF THE WARRANTS 

 CELLECTIS 

French société anonyme with a share capital of EUR. 1.054.115,85 

Registered office: 8 rue de la Croix Jarry, 75013 Paris, France 

 
  

SUBSCRIPTION FORM 
 Amount
and terms of the issuance of the warrant 
 Issuance at a total price of EUR. 30,000.00 of 50,000 warrants (hereafter the
“Warrants”), giving the right to subscribe a maximum number of 50,000 ordinary shares (hereafter the “Warrant Shares”), each of a nominal value of EUR. 0.05, at a fixed price of EUR. 6.00 each (issue premium
included), to be fully paid up in cash or by way of set off against receivables and the subscription of which has been reserved to the subscriber. 
 The
issuance has been decided by the board of directors of Cellectis on March 27, 2014 pursuant to the authorization granted to it by the extraordinary shareholders’ meeting of June 14, 2013. 

The terms and conditions of the Warrants are described in the warrant agreement executed by the subscriber and Cellectis on March 26, 2014. 

The subscription period is opened from March 26, 2014 to April 4, 2014 included. 

The amount of the subscription shall be paid in cash or by way of set off against receivables in accordance with applicable French law. 

—ooOoo— 
 The undersigned 

Trout Capital LLC, a limited liability company incorporated in the State of New York in the United States of America, having its registered office at 740
Broadway, 9th Floor, New York, NY 10003, United States, 
 acknowledging the terms and conditions of the Warrants, including: 

 

	 	•	 	that neither the Warrants nor the Warrant Shares have been, nor will be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) by reason of a specific exemption from the
registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the representations below; 

and representing and warranting to Cellectis as follows: 
  

	 	•	 	that it is acquiring the Warrants for investment for its own account, not as a nominee or agent, and not with the view to, or for resale in connection with, any distribution thereof, and that it has no present intention
of selling, granting any participation in, or otherwise distributing the same; 

  
 - 2 - 

	 	•	 	that it does not have any contract, undertaking, agreement or arrangement with any person or entity to sell, transfer or grant participation to such person or entity or to any third person or entity with respect to any
of the Warrants; 

  

	 	•	 	that it is an institutional “accredited investor” as defined in Regulation D, Rule 501(a) under the Securities Act, has such knowledge and experience in financial and business matters so that it is capable of
evaluating the merits and risks of its investment in Cellectis and it understands and acknowledges that an investment in Cellectis is highly speculative and involves substantial risks. It can bear the economic risk of its investment and is able,
without impairing its financial condition, to hold the Warrants and the Warrant Shares for an indefinite period of time and to suffer a complete loss of its investment; 

 

	 	•	 	that it has had an opportunity to ask questions of, and receive answers from, the officers of Cellectis concerning this Warrant Agreement, as well as its business, management and financial affairs, which questions were
answered to its satisfaction; 

  

	 	•	 	that it believes that it has received all the information it considers necessary or appropriate for deciding whether to receive Warrants. It acknowledges that any future plans and forward looking statements expressed by
Cellectis are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the future plans and forward looking statements will not materialize or will vary significantly from actual results. It also
acknowledges that it is relying solely on its own counsel and not on any statements or representations of Cellectis, or any agent or adviser of Cellectis for legal advice with respect to the subscription of the Warrants; 

 

	 	•	 	that the Warrants are being acquired by it in reliance on a private placement exemption from the registration requirements of the Securities Act and the Warrants and any Warrants Shares are and will be “restricted
securities” within the meaning of Rule 144(a)(3) under the Securities Act and that the exemption from registration provided under Rule 144 may not be available for resales by it of the Warrants or the Warrants Shares. Therefore, it further
agrees that if it wishes to dispose of or exchange any of the Warrants or Warrant Shares, it will not transfer any of the Warrants or Warrant Shares, directly or indirectly, unless such transfer is a transaction that is deemed to occur outside of
the United States under Regulation S under the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements, of the Securities Act. The Company may require, as a condition of allowing
any transfer, that the holder or transferee of the Warrants or Warrant Shares, as the case may be, provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which
opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Warrant or the Warrant Shares under the Securities Act; 

  
 - 3 - 

 hereby subscribes the Warrants and pays the amount of its subscription, i.e. EUR. 30,000.00, by way of set off
against receivables in accordance with applicable French law. 
  

	
	 Made in
 On

In two (2) copies

	
	  

	For Trout Capital LLC*
	By:
	Title:

  

	*	the signature shall be preceded by the following handwritten sentence: “Approval for formal and irrevocable subscription of 50,000 (fifty thousand) Warrants” 

  
 - 4 - 

 EXHIBIT 2 

EXERCISE NOTICE OF THE WARRANTS 

(Share subscription form) 
 CELLECTIS 

8 rue de la Croix Jarry 
 75013 Paris 

France 

[            ], [    ] 

Attention: André Choulika/Thierry Moulin 
 Trout Capital
LLC, a limited liability company incorporate in the State of New York in the United States of America, having its registered office at 740 Broadway, 9th Floor, New York, NY 10003, United States, 

holder of 50,000 Warrants, each giving right to subscribe for one ordinary share (each a “Warrant Share”) of Cellectis (the
“Company”) issued pursuant to the resolution of the board of directors of Cellectis held on March 24, 2014, 
 having examined the
terms and conditions of the Warrants, including: 
  

	 	•	 	that neither the Warrants nor the Warrant Shares have been, nor will be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) by reason of a specific exemption from the
registration provisions of the Securities Act and therefore the Warrants and the Warrants Shares are and will be “restricted securities” within the meaning of Rule 144(a)(3) under the Securities Act; 

 

	 	•	 	that the exemption from registration provided under Rule 144 may not be available for resales by it of the Warrants Shares; 

  

	 	•	 	therefore, it agrees that the Warrant Shares may only be transferred, directly or indirectly, in a transaction that is deemed to occur outside of the United States under Regulation S under the Securities Act, or
pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act; it agrees that the Company may require, as a condition of allowing any transfer, that the holder or transferee of the
Warrant Shares, as the case may be, provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the
effect that such transfer does not require registration of such transferred Warrant Shares under the Securities Act and that these restrictions have been noted in Cellectis’s share registry held by its registrar; 

hereby 
 exercises [_—_] Warrants 

 and 

subscribes consequently for [_—_] Warrant Shares of Cellectis, each of a nominal value of EUR.
0.05, for a subscription price per share of EUR. 6.00 share premium included, 
 pays, for this subscription, the total amount of EUR. [_—_], corresponding to the aggregate of the nominal value and the share premium of the above Warrant Shares, 

by wire transfer to Cellectis’s bank account opened at [_—_], Bank Code: [_—_], Desk Code: [_—_], Account: [_—_], Cle RIB:
[_—_], IBAN International Bank Account Number [_—_]. 
  

	
	 Made in
 On

In two copies

	
	  

	For Trout Capital LLC*
	By:
	Title:

  

	*	Signature preceded by: “Approval for formal and irrevocable subscription of [_—_] ordinary shares” (number of shares to be mentioned in both figures and
letters.) 

  
 - 2 -EX-10.10

 Exhibit 10.10 

CHANGE OF CONTROL PLAN 
 The executive and
employee change of control plan (the “Plan”) has been adopted by our board of directors on September 4, 2014 and was subsequently amended on December 11, 2014. 

The Plan is effective as from September 4, 2014 with respect to the concerned executives and will be effective towards the concerned employees upon the
execution by each concerned employee of an amendment to his or her employment agreement to this effect. 
 A free translation of the relevant excerpt of the
minutes of our board of directors’ meeting held on December 11, 2014 is presented on the following page. 

 CELLECTIS 

A French société anonyme with a share capital of EUR 1,470,986.05 

Registered office: 8, rue de la Croix Jarry – 75013 Paris - France 

428 859 052 R.C.S. Paris 
  

 
 Translated
excerpt of the minutes of the board of directors 
 held on December 11, 2014 

During its meeting held on December 11, 2014, the board of directors of Cellectis (the “Company”) has made the following decision: 

 Modifications of the circumstances in which a severance package should be paid by the Company to managers upon a change of control 

The chairman reports that his attention has been drawn to the need to clarify the circumstances in which the severance package approved by the board of
directors held on September 4, 2014 should be paid to the managers of the group upon a change of control. 
 The chairman reminds the directors the
list of the relevant managers together with their respective compensation levels: 
  

															
	First name	  	Last name	  	Position	  	 Annual

compensation

(gross)
	 	  	 Bonus (% of

annual

compensation)
	 	 	Comments
						
	 André
	  	 Choulika
	  	Chairman of the board of directors and CEO	  	 	240,000	  	  	 	80	% 	 	
	 Mathieu
	  	 Simon
	  	EVP	  	 	245,000	  	  	 	40	% 	 	contractual
	 David
	  	 Sourdive
	  	EVP	  	 	180,000	  	  	 	40	% 	 	
	 Philippe
	  	 Duchateau
	  	CSO	  	 	120,000	  	  	 	40	% 	 	
	 Marie-Bleuenn
	  	 Terrier
	  	GC	  	 	85,000	  	  	 	14	% 	 	(non contractual 2013 bonus)
	 Philippe
	  	 Valachs
	  	CS	  	 	144,000	  	  	 	40	% 	 	
	 Thierry
	  	 Moulin
	  	CFO	  	 	140,000	  	  	 	40	% 	 	
	 Delphine
	  	 Jay
	  	HR	  	 	110,000	  	  	 	12	% 	 	(non contractual 2013 bonus 2013)
	 Julia
	  	 Berretta
	  	BusDev	  	 	70,000	  	  	 	12	% 	 	(non contractual 2013 bonus)
	 Laurent
	  	 Poirot
	  	Innovation Manager	  	 	70,000	  	  	 	17	% 	 	(non contractual 2013 bonus)
	 Julianne
	  	 Smith
	  	VP CART Platform	  	 	80,000	  	  	 	21	% 	 	(non contractual 2013 bonus)

 The chairman also reminds the directors that the board of directors has, during its meeting held on
September 4, 2014, set this severance package at an amount equal to 24 months of gross fixed salary (or for executives, 24 months of compensation) increased by an amount equal to the maximum target bonus to which the employees or executives
concerned may be entitled for the year of their departure, or, in the absence of such a target bonus, 1.5 times the last annual bonus paid to them by the Company during the 12 months prior to their departure. 

Notwithstanding the above, the board of directors, upon recommandation of the compensation committee, decides that the severance package to be paid to
André Choulika, chief executive officer of Cellectis SA, shall amount to two years of compensation and two years of maximal target bonus to take into account the fact that André Choulika is not entitled to any legal or conventional
severance payments in the absence of an employment agreement having been entered into between himself and the Company. 
  This amount would be in
addition to any legal and conventional severance payments owed by the Company to the employees or executives concerned. 
  The Chairman suggests: 

  

	 	•	 	to extend the definition of a « change of control » triggering the payment of such a severance package from the crossing of the threshold of 50% of the share capital or voting rights only to all
circumstances qualifying as a change of control within the meaning of article L. 233-3 of the French Commercial code; and 

  

	 	•	 	with respect to managers having entered into an employment agreement with the Company, to clarify that their departure as a result of a significant reduction of their responsabilities would trigger the payment of the
abovementioned severance package only to the extent that such departure occurs within the 12-month period following a change of control; and 

   

	 	•	 	to extend from 12 to 36 months following a change of control the period during which the concerned managers would benefit from this severance package. 

This amount would thus be paid by the Company should any of the following events occur, it being provided that such triggering events replace and supersede
the triggering events approved by the board of directors during its meeting held on September 4, 2014: 
   

	 	•	 	with respect to all managers, whether they are executives of the Company or have entered into an employment agreement with the Company: should the employees or executives concerned not be renewed or be dismissed
other than for gross misconduct (faute lourde) within the meaning of French labor law within the 36-month period following a change of control of the Company within the meaning of article L. 233-3 of the French Commercial code.

  

	 	•	 	with respect to executives only: should they resign within the abovementioned 36-month period as a result of a significant reduction of their duties or compensation. 

The president indicates that the granting to David Sourdives, deputy chief executive officer, and to himself of the severance package qualifies as a related
party agreement which is therefore subject to the prior approval of the board of directors. 
 The board of directors, after discussions, unanimously: 

 

	 	•	 	approves to put into place the abovementioned amendments relating to the circumstances in which a severance package shall be paid to managers of the Company upon a change of control, it being specified that
André Choulika et David Sourdives, did not participate to the vote, 

*        *        * 

*        * 

*

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]